Dr. Ehab AlShamleh is a pharmaceutical executive and technical leader with over two decades of experience in sterile manufacturing, drug development, and regulatory operations. He has directed the launch of more than 100 injectable products across global markets, including complex biologics and lyophilized platforms. His leadership spans facility expansion, technology transfer, and strategic vendor partnerships across MENA, North America, and Europe.

Dr. AlShamleh is the Founder and Principal Consultant at CMC Strategy Partners, advising biopharma ventures on process development, scale-up, and regulatory compliance. Previously, he served as Senior Director at IMV Inc., where he led CMC operations for late-stage clinical assets, and held senior roles at MS Pharma, Baxter, and Hikma Pharmaceuticals. His expertise includes GMP governance, operational excellence, and cross-functional team development.

Dr. AlShamleh holds a Master of Technology in Entrepreneurship and Innovation from Saint Mary’s University, a Master of Science in Pharmaceutical Sciences, and a Bachelor of Pharmacy. He is certified in production and inventory management and actively engaged with global professional bodies including AAPS, ISPE, PDA, and ASQ. His work continues to shape biotech manufacturing strategy and clinical readiness across emerging and established markets.